Skip to main content
Fig. 8 | Arthritis Research & Therapy

Fig. 8

From: Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

Fig. 8

Effects of Emab on CD10CD27+ and CD10+CD27–/+ cell activation and cell survival. Sorted B-cell subsets were left untreated or stimulated with R848 anti-human F(ab′)2 IgM or a combination of R848 plus anti-IgM in the presence of Emab or isotype control Ab. Cells were cultured for 5 days and surface expression of CD38 and CD27 (a) and frequencies of live cells in culture (b) were analyzed by flow cytometry. ***p < 0.001, as determined by two-way ANOVA with Bonferroni post test. Emab epratuzumab

Back to article page